Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.
Identifieur interne : 001C54 ( PubMed/Curation ); précédent : 001C53; suivant : 001C55Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.
Auteurs : S. Sharmila [Inde] ; I. Christiana ; P. Kiran ; M V R. Reddy ; K. Sankaran ; P. KalirajSource :
- Parasite immunology [ 1365-3024 ] ; 2013.
Descripteurs français
- KwdFr :
- Activation des lymphocytes, Animaux, Anticorps antihelminthe (immunologie), Anticorps antihelminthe (sang), Antigènes d'helminthe (immunologie), Brugia malayi (immunologie), Cytokines (immunologie), Cytokines (métabolisme), Déterminants antigéniques des lymphocytes T (immunologie), Escherichia coli (génétique), Filariose lymphatique (), Filariose lymphatique (immunologie), Glycérides (immunologie), Humains, Immunisation, Ingénierie des protéines, Larve (immunologie), Lipides (immunologie), Lymphocytes T (immunologie), Murinae, Mâle, Protéines recombinantes (immunologie), Vaccins (immunologie).
- MESH :
- génétique : Escherichia coli.
- immunologie : Anticorps antihelminthe, Antigènes d'helminthe, Brugia malayi, Cytokines, Déterminants antigéniques des lymphocytes T, Filariose lymphatique, Glycérides, Larve, Lipides, Lymphocytes T, Protéines recombinantes, Vaccins.
- métabolisme : Cytokines.
- sang : Anticorps antihelminthe.
- Activation des lymphocytes, Animaux, Filariose lymphatique, Humains, Immunisation, Ingénierie des protéines, Murinae, Mâle.
English descriptors
- KwdEn :
- Animals, Antibodies, Helminth (blood), Antibodies, Helminth (immunology), Antigens, Helminth (immunology), Brugia malayi (immunology), Cytokines (immunology), Cytokines (metabolism), Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (prevention & control), Epitopes, T-Lymphocyte (immunology), Escherichia coli (genetics), Glycerides (immunology), Humans, Immunization, Larva (immunology), Lipids (immunology), Lymphocyte Activation, Male, Murinae, Protein Engineering, Recombinant Proteins (immunology), T-Lymphocytes (immunology), Vaccines (immunology).
- MESH :
- chemical , blood : Antibodies, Helminth.
- chemical , immunology : Antibodies, Helminth, Antigens, Helminth, Cytokines, Epitopes, T-Lymphocyte, Glycerides, Lipids, Recombinant Proteins, Vaccines.
- genetics : Escherichia coli.
- immunology : Brugia malayi, Elephantiasis, Filarial, Larva, T-Lymphocytes.
- chemical , metabolism : Cytokines.
- prevention & control : Elephantiasis, Filarial.
- Animals, Humans, Immunization, Lymphocyte Activation, Male, Murinae, Protein Engineering.
Abstract
As in many other parasitic diseases, efficacious vaccine for lymphatic filariasis has been elusive for want of new approaches leaving billions of people either debilitated or at risk. With multiple B- and T-cell epitopes, the abundant larval transcript-2 (ALT-2) of the filarial worm, Brugia malayi, has been shown to be a promising immunoprophylactic target. To enhance its efficacy, it was lipid modified using our recently developed protein engineering tool, which then offered 30% more immunoprotection (49 vs. 79%) in Mastomys coucha model. Sustained high levels of IFN-γ (about 100 times) and high antibody titres (10-fold) elicited by lipid-modified ALT-2, as compared to the native form, indicated the maintenance of Th1/Th2 balance that is impaired in filariasis. Thus, this study provides the basis for developing efficacious vaccines for filariasis and other parasitic diseases by exploiting bacterial lipid modification.
DOI: 10.1111/pim.12034
PubMed: 23495791
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C54
Links to Exploration step
pubmed:23495791Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.</title><author><name sortKey="Sharmila, S" sort="Sharmila, S" uniqKey="Sharmila S" first="S" last="Sharmila">S. Sharmila</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Biotechnology, Anna University, Chennai, Tamilnadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Centre for Biotechnology, Anna University, Chennai, Tamilnadu</wicri:regionArea></affiliation></author><author><name sortKey="Christiana, I" sort="Christiana, I" uniqKey="Christiana I" first="I" last="Christiana">I. Christiana</name></author><author><name sortKey="Kiran, P" sort="Kiran, P" uniqKey="Kiran P" first="P" last="Kiran">P. Kiran</name></author><author><name sortKey="Reddy, M V R" sort="Reddy, M V R" uniqKey="Reddy M" first="M V R" last="Reddy">M V R. Reddy</name></author><author><name sortKey="Sankaran, K" sort="Sankaran, K" uniqKey="Sankaran K" first="K" last="Sankaran">K. Sankaran</name></author><author><name sortKey="Kaliraj, P" sort="Kaliraj, P" uniqKey="Kaliraj P" first="P" last="Kaliraj">P. Kaliraj</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23495791</idno><idno type="pmid">23495791</idno><idno type="doi">10.1111/pim.12034</idno><idno type="wicri:Area/PubMed/Corpus">001C54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C54</idno><idno type="wicri:Area/PubMed/Curation">001C54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.</title><author><name sortKey="Sharmila, S" sort="Sharmila, S" uniqKey="Sharmila S" first="S" last="Sharmila">S. Sharmila</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Biotechnology, Anna University, Chennai, Tamilnadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Centre for Biotechnology, Anna University, Chennai, Tamilnadu</wicri:regionArea></affiliation></author><author><name sortKey="Christiana, I" sort="Christiana, I" uniqKey="Christiana I" first="I" last="Christiana">I. Christiana</name></author><author><name sortKey="Kiran, P" sort="Kiran, P" uniqKey="Kiran P" first="P" last="Kiran">P. Kiran</name></author><author><name sortKey="Reddy, M V R" sort="Reddy, M V R" uniqKey="Reddy M" first="M V R" last="Reddy">M V R. Reddy</name></author><author><name sortKey="Sankaran, K" sort="Sankaran, K" uniqKey="Sankaran K" first="K" last="Sankaran">K. Sankaran</name></author><author><name sortKey="Kaliraj, P" sort="Kaliraj, P" uniqKey="Kaliraj P" first="P" last="Kaliraj">P. Kaliraj</name></author></analytic><series><title level="j">Parasite immunology</title><idno type="eISSN">1365-3024</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Helminth (blood)</term><term>Antibodies, Helminth (immunology)</term><term>Antigens, Helminth (immunology)</term><term>Brugia malayi (immunology)</term><term>Cytokines (immunology)</term><term>Cytokines (metabolism)</term><term>Elephantiasis, Filarial (immunology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Epitopes, T-Lymphocyte (immunology)</term><term>Escherichia coli (genetics)</term><term>Glycerides (immunology)</term><term>Humans</term><term>Immunization</term><term>Larva (immunology)</term><term>Lipids (immunology)</term><term>Lymphocyte Activation</term><term>Male</term><term>Murinae</term><term>Protein Engineering</term><term>Recombinant Proteins (immunology)</term><term>T-Lymphocytes (immunology)</term><term>Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation des lymphocytes</term><term>Animaux</term><term>Anticorps antihelminthe (immunologie)</term><term>Anticorps antihelminthe (sang)</term><term>Antigènes d'helminthe (immunologie)</term><term>Brugia malayi (immunologie)</term><term>Cytokines (immunologie)</term><term>Cytokines (métabolisme)</term><term>Déterminants antigéniques des lymphocytes T (immunologie)</term><term>Escherichia coli (génétique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (immunologie)</term><term>Glycérides (immunologie)</term><term>Humains</term><term>Immunisation</term><term>Ingénierie des protéines</term><term>Larve (immunologie)</term><term>Lipides (immunologie)</term><term>Lymphocytes T (immunologie)</term><term>Murinae</term><term>Mâle</term><term>Protéines recombinantes (immunologie)</term><term>Vaccins (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Helminth</term><term>Antigens, Helminth</term><term>Cytokines</term><term>Epitopes, T-Lymphocyte</term><term>Glycerides</term><term>Lipids</term><term>Recombinant Proteins</term><term>Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antihelminthe</term><term>Antigènes d'helminthe</term><term>Brugia malayi</term><term>Cytokines</term><term>Déterminants antigéniques des lymphocytes T</term><term>Filariose lymphatique</term><term>Glycérides</term><term>Larve</term><term>Lipides</term><term>Lymphocytes T</term><term>Protéines recombinantes</term><term>Vaccins</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Brugia malayi</term><term>Elephantiasis, Filarial</term><term>Larva</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Immunization</term><term>Lymphocyte Activation</term><term>Male</term><term>Murinae</term><term>Protein Engineering</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation des lymphocytes</term><term>Animaux</term><term>Filariose lymphatique</term><term>Humains</term><term>Immunisation</term><term>Ingénierie des protéines</term><term>Murinae</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As in many other parasitic diseases, efficacious vaccine for lymphatic filariasis has been elusive for want of new approaches leaving billions of people either debilitated or at risk. With multiple B- and T-cell epitopes, the abundant larval transcript-2 (ALT-2) of the filarial worm, Brugia malayi, has been shown to be a promising immunoprophylactic target. To enhance its efficacy, it was lipid modified using our recently developed protein engineering tool, which then offered 30% more immunoprotection (49 vs. 79%) in Mastomys coucha model. Sustained high levels of IFN-γ (about 100 times) and high antibody titres (10-fold) elicited by lipid-modified ALT-2, as compared to the native form, indicated the maintenance of Th1/Th2 balance that is impaired in filariasis. Thus, this study provides the basis for developing efficacious vaccines for filariasis and other parasitic diseases by exploiting bacterial lipid modification.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23495791</PMID><DateCreated><Year>2013</Year><Month>07</Month><Day>01</Day></DateCreated><DateCompleted><Year>2014</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-3024</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>7-8</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Parasite immunology</Title><ISOAbbreviation>Parasite Immunol.</ISOAbbreviation></Journal><ArticleTitle>Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.</ArticleTitle><Pagination><MedlinePgn>201-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pim.12034</ELocationID><Abstract><AbstractText>As in many other parasitic diseases, efficacious vaccine for lymphatic filariasis has been elusive for want of new approaches leaving billions of people either debilitated or at risk. With multiple B- and T-cell epitopes, the abundant larval transcript-2 (ALT-2) of the filarial worm, Brugia malayi, has been shown to be a promising immunoprophylactic target. To enhance its efficacy, it was lipid modified using our recently developed protein engineering tool, which then offered 30% more immunoprotection (49 vs. 79%) in Mastomys coucha model. Sustained high levels of IFN-γ (about 100 times) and high antibody titres (10-fold) elicited by lipid-modified ALT-2, as compared to the native form, indicated the maintenance of Th1/Th2 balance that is impaired in filariasis. Thus, this study provides the basis for developing efficacious vaccines for filariasis and other parasitic diseases by exploiting bacterial lipid modification.</AbstractText><CopyrightInformation>© 2013 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharmila</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Biotechnology, Anna University, Chennai, Tamilnadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christiana</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kiran</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>M V R</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Sankaran</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kaliraj</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parasite Immunol</MedlineTA><NlmUniqueID>7910948</NlmUniqueID><ISSNLinking>0141-9838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005989">Glycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>21I29V2935</RegistryNumber><NameOfSubstance UI="C114956">2-palmitoylglycerol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005989" MajorTopicYN="N">Glycerides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007814" MajorTopicYN="N">Larva</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051189" MajorTopicYN="N">Murinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015202" MajorTopicYN="N">Protein Engineering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brugia malayi</Keyword><Keyword MajorTopicYN="N">Mastomys</Keyword><Keyword MajorTopicYN="N">abundant larval transcript</Keyword><Keyword MajorTopicYN="N">bacterial lipid modification</Keyword><Keyword MajorTopicYN="N">immunoprophylaxis</Keyword><Keyword MajorTopicYN="N">lymphatic filariasis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>02</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23495791</ArticleId><ArticleId IdType="doi">10.1111/pim.12034</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001C54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23495791
|texte= Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23495791" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |